Brian E. Libby
United States Military Academy
9 Papers
132 Citations
Brian E. Libby is an academic researcher from United States Military Academy. The author has contributed to research in topics: Hyperalgesia & Benzamidines. The author has an hindex of 8, co-authored 9 publications. Previous affiliations of Brian E. Libby include Merck & Co..
Chat about Author
Papers
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Nigel J. Liverton,John W. Butcher,Christopher F. Claiborne,David A. Claremon,Brian E. Libby,Kevin Nguyen,Steven M. Pitzenberger,H. G. Selnick,Garry R. Smith,Andrew J. Tebben,Joe P. Vacca,Sandor L. Varga,Agarwal L,K B Dancheck,A J Forsyth,D S Fletcher,B. Frantz,W A Hanlon,C F Harper,S J Hofsess,M Kostura,Jiunn H. Lin,S Luell,Edward A. O'Neill,Stephen J. O'Keefe +24 more
TL;DR: 48, a potent and selective p38 MAP kinase inhibitor which inhibits lipopolysaccharide-stimulated release of TNF-alpha from human blood with an IC50 2.2 nM shows good oral bioavailability in rat and rhesus monkey, and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model.
230
Orally Efficacious NR2B-Selective NMDA Receptor Antagonists
Christopher F. Claiborne,John A. McCauley,Brian E. Libby,Neil Roy Curtis,Helen J. Diggle,Janusz Jozef Kulagowski,Stuart R. Michelson,Kenneth D. Anderson,David A. Claremon,Roger M. Freidinger,Rodney A. Bednar,Scott D. Mosser,Stanley L. Gaul,Thomas M. Connolly,Cindra L. Condra,Bohumil Bednar,Gary L. Stump,Joseph J. Lynch,Alison J. Macaulay,Keith A. Wafford,Kenneth S. Koblan,Nigel J. Liverton +21 more
TL;DR: A novel series of benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity and is orally active in a carrageenan-induced rat hyperalgesia model of pain and shows no motor coordination side effects.
60
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Nigel J. Liverton,Rodney A. Bednar,Bohumil Bednar,John W. Butcher,Christopher F. Claiborne,David A. Claremon,Michael E. Cunningham,Anthony G. DiLella,Stanley L. Gaul,Brian E. Libby,Elizabeth A. Lyle,Joseph J. Lynch,John A. McCauley,Scott D. Mosser,Kevin Nguyen,Gary L. Stump,Hong Sun,Hao Wang,James Yergey,Kenneth S. Koblan +19 more
TL;DR: In this article, a novel series of NR2B subtype selective N-methyl-d-aspartate (NMDA) antagonists was reported, which improved off-target activity profile and oral bioavailability in multiple species coupled with good brain penetration.
45
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.
Kevin Nguyen,Christopher F. Claiborne,John A. McCauley,Brian E. Libby,David A. Claremon,Rodney A. Bednar,Scott D. Mosser,Stanley L. Gaul,Thomas M. Connolly,Cindra L. Condra,Bohumil Bednar,Gary L. Stump,Joseph J. Lynch,Kenneth S. Koblan,Nigel J. Liverton +14 more
TL;DR: A novel series of cyclic benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity and is orally active in a carrageenan-induced rat hyperalgesia model of pain.
24
Patent
Aryl amidines, compositions containing such compounds and methods of use
Christopher F. Claiborne,Nigel J. Liverton,Brian E. Libby,Neil Roy Curtis,Janusz Jozef Kulagowski +4 more
- 08 May 2000
TL;DR: In this paper, a list of ingredients represented by formula (I): or a pharmaceutically acceptable salt or hydrate thereof, and their compositions and methods of treatment are also included.
13